Payment overview · 2025
General Payments
$379.73
14 reported records · 7 companies
Healthcare provider profile · identity verified
Raul Caudillo, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · EL PASO, TX · NPI 1619589165
Verified facts
What the public records show
CMS Open Payments records show Raul Caudillo, FNP received $379.73 in general payments during 2025 across 14 reported records.
Amgen Inc. accounted for 42.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $160.73 | 42.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $55.52 | 14.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.69 | 13.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.56 | 10.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.75 | 9.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.01 | 6.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.47 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $379.73 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $146.20 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $66.79 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $35.75 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $30.85 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $24.67 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.46 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.46 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.01 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $23.01 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.53 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.53 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 86 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 27 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | 14 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
49 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
71 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 539 | 236 |
| Lisinopril | Lisinopril | 382 | 156 |
| Metformin Hcl | Metformin Hcl | 349 | 157 |
| Amlodipine Besylate | Amlodipine Besylate | 336 | 137 |
| Losartan Potassium | Losartan Potassium | 322 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 297 | 122 |
| Gabapentin | Gabapentin | 292 | 134 |
| Alendronate Sodium | Alendronate Sodium | 278 | 115 |
| Alprazolam | Alprazolam | 184 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 181 | 86 |
| Simvastatin | Simvastatin | 179 | 78 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 175 | 121 |
| Glipizide | Glipizide | 171 | 75 |
| Pioglitazone Hcl | Pioglitazone Hcl | 161 | 67 |
| Carvedilol | Carvedilol | 154 | 68 |
| Omeprazole | Omeprazole | 146 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 69 |
| Famotidine | Famotidine | 132 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 72 |
| Finasteride | Finasteride | 125 | 58 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 109 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 108 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 100 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 99 | 41 |
| Tramadol Hcl | Tramadol Hcl | 98 | 28 |
| Azithromycin | Azithromycin | 97 | 90 |
| Januvia | Sitagliptin Phosphate | 94 | 30 |
| Dicyclomine Hcl | Dicyclomine Hcl | 90 | 52 |
| Citalopram Hbr | Citalopram Hydrobromide | 88 | 45 |
| Jardiance | Empagliflozin | 86 | 33 |
| Prednisone | Prednisone | 80 | 58 |
| Telmisartan | Telmisartan | 78 | 25 |
| Meclizine Hcl | Meclizine Hcl | 71 | 32 |
| Trulicity | Dulaglutide | 71 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 52 |
| Fenofibrate | Fenofibrate | 69 | 37 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 60 |
| Ibuprofen | Ibuprofen | 64 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 26 |
| Furosemide | Furosemide | 60 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 44 |
| Naproxen | Naproxen | 59 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 26 |
| Trazodone Hcl | Trazodone Hcl | 57 | 18 |
| Donepezil Hcl | Donepezil Hcl | 53 | 24 |
| Sertraline Hcl | Sertraline Hcl | 53 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 50 | 20 |
| Farxiga | Dapagliflozin Propanediol | 49 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 18 |
| Montelukast Sodium | Montelukast Sodium | 46 | 22 |
| Cephalexin | Cephalexin | 44 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 25 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 44 | 25 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 44 | 21 |
| Clonazepam | Clonazepam | 42 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 37 |
| Pregabalin | Pregabalin | 40 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 33 |
| Eliquis | Apixaban | 36 | 16 |
| Ozempic | Semaglutide | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | 13 |
| Meloxicam | Meloxicam | 33 | 20 |
| Ondansetron Odt | Ondansetron | 33 | 29 |
| Memantine Hcl | Memantine Hcl | 32 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | 16 |
| Mupirocin | Mupirocin | 30 | 28 |
| Mirtazapine | Mirtazapine | 29 | 14 |
| Nifedipine Er | Nifedipine | 29 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 28 | 20 |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Linzess | Linaclotide | 27 | 14 |
| Dexamethasone | Dexamethasone | 26 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | 11 |
| Torsemide | Torsemide | 26 | 14 |
| Spironolactone | Spironolactone | 25 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 22 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 18 |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | 16 |
| Methylprednisolone | Methylprednisolone | 18 | 17 |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 17 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 17 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Ciclopirox | Ciclopirox | 15 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ezetimibe | Ezetimibe | 14 | 11 |
| Felodipine Er | Felodipine | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Prolia | Denosumab | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $379.73 · 14 records | Amgen Inc. | AIRSUPRA, CAPVAXIVE, CREON, EVENITY, GARDASIL 9, JARDIANCE, LINZESS, MOUNJARO, OTEZLA, REPATHA, The Cologuard Plus Collection Kit, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error